Saturday, December 13, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Blockchain

Coinbase Charts a New Course with Major Platform Expansion

Robert Sasse by Robert Sasse
December 13, 2025
in Blockchain, Crypto Stocks, Tech & Software, Trading & Momentum
0
Coinbase Stock
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Coinbase is preparing for a significant strategic shift. The cryptocurrency exchange has scheduled a “System Update” event for December 17, 2025, where it plans to unveil two new product categories: prediction markets and tokenized equities. This announcement arrives during a period of waning interest in digital assets and intensifying competitive pressure across the sector.

Financial Resilience Amid Market Headwinds

Despite a challenging quarter for its share price, which declined over 16% as Bitcoin fell to $85,000 in early December—its lowest point since March 2025—Coinbase posted robust financial results for Q3 2025. The company reported a 58% surge in total revenue, reaching $1.9 billion, with transaction volume hitting $1 billion. Adjusted EBITDA stood at $801 million, while net profit was $433 million. This performance highlights the firm’s ability to generate solid earnings even as a liquidity crisis in October exposed vulnerabilities within the broader crypto industry.

The company’s current market capitalization is approximately $72 billion, supported by a net margin of 42.4%. Its inclusion in the S&P 500 earlier this year further cemented its standing within the traditional financial landscape.

Diversifying Beyond Crypto Volatility

The upcoming product launches are a deliberate part of Coinbase’s strategy to reduce its reliance on volatile cryptocurrency trading revenues. The company is steadily building more stable income streams; revenue from stablecoins, particularly USDC, now constitutes 22% of total revenue. Furthermore, its proprietary Layer-2 blockchain, Base, has achieved profitability.

Should investors sell immediately? Or is it worth buying Coinbase?

CEO Brian Armstrong’s vision of an “Everything Exchange”—a platform extending far beyond basic crypto trading—is being advanced through strategic acquisitions. The purchases of Deribit and Echo have significantly expanded Coinbase’s derivatives and institutional business offerings.

Strategic Partnerships and In-House Development

For its new prediction markets, Coinbase is partnering with Kalshi, a regulated U.S.-based provider. This collaboration is non-exclusive; Kalshi is already active via Robinhood and is in discussions with other industry participants. Notably, competitor Gemini received CFTC approval for a regulated prediction market this week, and Robinhood has announced its own platform for futures and derivatives.

In contrast, Coinbase is developing its tokenized equities offering entirely in-house. This approach differentiates it from rivals like Robinhood, Gemini, and Kraken, all of which have launched similar products for non-U.S. users in the past twelve months by relying on external partners. The growing interest in this asset class is evidenced by a 32% monthly increase in the transfer volume of blockchain-based stocks, which recently reached $1.45 billion.

The December event will be a critical test of whether these innovations can successfully transform Coinbase from a pure trading venue into a comprehensive financial services provider.

Ad

Coinbase Stock: Buy or Sell?! New Coinbase Analysis from December 13 delivers the answer:

The latest Coinbase figures speak for themselves: Urgent action needed for Coinbase investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 13.

Coinbase: Buy or sell? Read more here...

Tags: Coinbase
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

The Trade Desk Stock
Analysis

The Trade Desk: A Premium Stock Under Scrutiny

December 13, 2025
Amazon Stock
AI & Quantum Computing

Amazon’s Aggressive AI Expansion: Balancing Massive Investment with Market Expectations

December 13, 2025
Purple Innovation Stock
Analysis

Purple Innovation Stock Under Scrutiny Amid Strategic Review

December 13, 2025
Next Post
Beyond Meat Stock

Beyond Meat Shares Face Mounting Pressure as Legal and Market Woes Converge

Uranium Energy Stock

Uranium Energy's Strategic Pivot: Building Inventory Amid Policy Shifts

Purple Innovation Stock

Purple Innovation Stock Under Scrutiny Amid Strategic Review

Recommended

iShares MSCI EAFE ETF Stock

Heightened Volatility Looms for the iShares MAFE ETF

1 week ago
Cryptocurrency Stock Bull Market

Title Bitdeer Reports Record Revenue Growth in Q4

2 years ago
Construction Stock

Construction Equity Defies Earnings Miss with Record Rally

3 months ago

Diana Shipping Inc Secures Time Charter Contract for mv Maera

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

UnitedHealth Faces Mounting Legal and Financial Pressures

The Trade Desk: A Premium Stock Under Scrutiny

Amazon’s Aggressive AI Expansion: Balancing Massive Investment with Market Expectations

Purple Innovation Stock Under Scrutiny Amid Strategic Review

Uranium Energy’s Strategic Pivot: Building Inventory Amid Policy Shifts

Beyond Meat Shares Face Mounting Pressure as Legal and Market Woes Converge

Trending

CureVac Stock
Analysis

CureVac Shareholders Face a Critical Deadline

by Felix Baarz
December 13, 2025
0

For remaining investors in CureVac, the clock is ticking down to a decisive moment. The company's journey...

Regional Management Stock

Conflicting Cues Emerge for Regional Management Investors

December 13, 2025
Immunovant Inc Stock

Immunovant Secures Major Funding to Advance Key Drug Candidate

December 13, 2025
Unitedhealth Stock

UnitedHealth Faces Mounting Legal and Financial Pressures

December 13, 2025
The Trade Desk Stock

The Trade Desk: A Premium Stock Under Scrutiny

December 13, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • CureVac Shareholders Face a Critical Deadline
  • Conflicting Cues Emerge for Regional Management Investors
  • Immunovant Secures Major Funding to Advance Key Drug Candidate

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com